MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc

NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company

NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuatio

NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regul

NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript

NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026

NeuroPace NASDAQ: NPCE reported second-quarter revenue growth driven by continued adoption of its RN

NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus

NeuroPace (NASDAQ:NPCE) raises FY2026 sales outlook from $99.000 million-$101.000 million to $99.500

NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.18) per share which beat the analyst consen

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc

Gainers Autonomix Medical (NASDAQ:AMIX) shares moved upwards by 62.5% to $4.47 during Wednesday&#39

US stock futures mixed, Dow up 0.1%. Avis Budget Group (CAR) shares down 13.3% after missing earning

HC Wainwright & Co. analyst Yi Chen reiterates NeuroPace (NASDAQ:NPCE) with a Buy and maintai

NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopa

NeuroPace NASDAQ: NPCE said the U.S. Food and Drug Administration determined that its premarket appr

Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc

Mizuho analyst Anthony Petrone initiates coverage on NeuroPace (NASDAQ:NPCE) with a Outperform ra

NPCE's RNS adoption, referral growth and AI innovation support expansion, while IGE timing and inves

The mean of analysts' price targets for NeuroPace (NPCE) points to a 27.9% upside in the stock. Whil

NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?

NPCE rides strong RNS adoption and AI tools nearing FDA review, with a mid-2026 IGE decision offerin

NeuroPace wins FDA OK for ECoG Assistant, its first AI feature for epilepsy care, leveraging RNS EEG

--ASSFN program to feature thalamic neuromodulation, NAUTILUS data in idiopathic generalized epileps

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company foc

NeuroPace exits DIXI, doubles down on RNS as Q1 narrows losses and lifts 2026 guidance, Medicare and

NeuroPace tightens focus on its RNS epilepsy implant, exits DIXI distribution and pushes AI + cloud

HC Wainwright & Co. analyst Yi Chen maintains NeuroPace (NASDAQ:NPCE) with a Buy and raises t

NeuroPace (NASDAQ:NPCE) raises FY2026 sales outlook from $98.000 million-$100.000 million to $99.000

NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.20) per share which beat the analyst consen

NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.08) per share which beat the analyst consen

HC Wainwright & Co. analyst Yi Chen maintains NeuroPace (NASDAQ:NPCE) with a Buy and raises t

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people

UBS analyst Priya Sachdeva maintains NeuroPace (NASDAQ:NPCE) with a Buy and raises the price targ

JP Morgan analyst Rohin Patel maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the

-- First randomized controlled trial of neuromodulation in drug-resistant idiopathic generalized epi

JP Morgan analyst Rohin Patel maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the

Wells Fargo analyst Vik Chopra maintains NeuroPace (NASDAQ:NPCE) with a Overweight and raises the